Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used for a novel Adeno-Associated Virus (AAV) gene therapy, GA-002, aimed at curing GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM).
Lead Product(s): GA-002
Therapeutic Area: Rare Diseases and Disorders Product Name: GA-002
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Solve GNE
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 14, 2023